Heat Biologics disappoints

Discussion in 'Pharma/Biotech Companies - Stock Discussions' started by Harrison Lockridge, Dec 2, 2016 at 1:01 AM.

  1. #1 Harrison Lockridge, Dec 2, 2016 at 1:01 AM
    Harrison Lockridge

    Harrison Lockridge new user

    Joined:
    Nov 29, 2016
    Messages:
    1
    Likes Received:
    0
    Heat Biologics Inc. (Nasdaq: HTBX) reported disappointing results from a Phase 2 trial of its bladder cancer treatment HS-410. Shares of the biopharmaceutical plummeted $1.84 to close at $1.03.
     
    Quote

Reply to Thread